BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

PURPOSE: Homologous DNA repair–deficient (HRD) ovarian cancers (OCs), including those with BRCA1/2 mutations, have higher levels of genetic instability, potentially resulting in higher immunogenicity, and have been suggested to respond better to immune checkpoint inhibitors (ICIs) than homologous DN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Principais autores: Liu, Ying L., Selenica, Pier, Zhou, Qin, Iasonos, Alexia, Callahan, Margaret, Feit, Noah Z., Boland, Julia, Vazquez-Garcia, Ignacio, Mandelker, Diana, Zehir, Ahmet, Burger, Robert A., Powell, Daniel J., Friedman, Claire, Cadoo, Karen, Grisham, Rachel, Konner, Jason A., O’Cearbhaill, Roisin E., Aghajanian, Carol, Reis-Filho, Jorge S., Weigelt, Britta, Zamarin, Dmitriy
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446408/
https://ncbi.nlm.nih.gov/pubmed/32923884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00069
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados